BR112020006246A2 - Método para controle do peso de um sujeito em necessidade - Google Patents

Método para controle do peso de um sujeito em necessidade Download PDF

Info

Publication number
BR112020006246A2
BR112020006246A2 BR112020006246-4A BR112020006246A BR112020006246A2 BR 112020006246 A2 BR112020006246 A2 BR 112020006246A2 BR 112020006246 A BR112020006246 A BR 112020006246A BR 112020006246 A2 BR112020006246 A2 BR 112020006246A2
Authority
BR
Brazil
Prior art keywords
semagglutide
week
use according
fact
subject
Prior art date
Application number
BR112020006246-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Maria Kabisch
Thomas Hansen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020006246(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of BR112020006246A2 publication Critical patent/BR112020006246A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112020006246-4A 2017-10-12 2018-10-10 Método para controle do peso de um sujeito em necessidade BR112020006246A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17196254.1 2017-10-12
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Publications (1)

Publication Number Publication Date
BR112020006246A2 true BR112020006246A2 (pt) 2021-03-30

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020006246-4A BR112020006246A2 (pt) 2017-10-12 2018-10-10 Método para controle do peso de um sujeito em necessidade

Country Status (18)

Country Link
US (4) US12029779B2 (enExample)
EP (1) EP3694538A1 (enExample)
JP (2) JP7148605B2 (enExample)
KR (1) KR20200069316A (enExample)
CN (4) CN119838000A (enExample)
AU (2) AU2018348929B2 (enExample)
BR (1) BR112020006246A2 (enExample)
CA (1) CA3078652A1 (enExample)
CL (1) CL2020000812A1 (enExample)
IL (3) IL322968A (enExample)
MA (1) MA50358A (enExample)
MX (3) MX2020003049A (enExample)
MY (1) MY204827A (enExample)
PH (1) PH12020550185A1 (enExample)
SG (1) SG11202002841PA (enExample)
TW (1) TWI842681B (enExample)
WO (1) WO2019072941A1 (enExample)
ZA (3) ZA202503387B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50358A (fr) * 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale
AU2021208601B2 (en) * 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20240197700A1 (en) * 2021-03-29 2024-06-20 Sanford Health Methods and Compositions for Treating Lysosomal Storage Disorders
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
WO2024252134A1 (en) * 2023-06-05 2024-12-12 Closed Loop Medicine Ltd Dosing of incretin pathway drugs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
MX2008013216A (es) 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
LT2373681T (lt) 2008-12-10 2017-04-10 Glaxosmithkline Llc Albiglutido farmacinės kompozicijos
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP2013514322A (ja) 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
JP2014520159A (ja) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
DK2866825T3 (da) * 2012-07-01 2020-06-08 Novo Nordisk As Anvendelse af langstidsvirkende glp-1-peptider
PT2991671T (pt) * 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
EP3648762A4 (en) 2017-08-04 2021-03-24 Ovid Therapeutics, Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED DISEASES
MA50358A (fr) * 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management

Also Published As

Publication number Publication date
WO2019072941A1 (en) 2019-04-18
MX2020003049A (es) 2020-07-27
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
JP7475398B2 (ja) 2024-04-26
JP2022132414A (ja) 2022-09-08
JP2020536854A (ja) 2020-12-17
ZA202503388B (en) 2025-09-25
ZA202503387B (en) 2025-09-25
RU2020114960A3 (enExample) 2022-02-11
IL273470A (en) 2020-05-31
TWI842681B (zh) 2024-05-21
US12029779B2 (en) 2024-07-09
IL322969A (en) 2025-10-01
US12295988B2 (en) 2025-05-13
TW201914611A (zh) 2019-04-16
MX2025002189A (es) 2025-04-02
JP7148605B2 (ja) 2022-10-05
IL322968A (en) 2025-10-01
AU2018348929A1 (en) 2020-05-07
EP3694538A1 (en) 2020-08-19
CN111212657A (zh) 2020-05-29
US20240316159A1 (en) 2024-09-26
ZA202503350B (en) 2025-09-25
CA3078652A1 (en) 2019-04-18
CN119950682A (zh) 2025-05-09
US20240415935A1 (en) 2024-12-19
US20200237876A1 (en) 2020-07-30
MX2025002188A (es) 2025-04-02
MA50358A (fr) 2020-08-19
AU2018348929B2 (en) 2025-02-27
CN119838000A (zh) 2025-04-18
MY204827A (en) 2024-09-18
CN120241968A (zh) 2025-07-04
KR20200069316A (ko) 2020-06-16
US20250235511A1 (en) 2025-07-24
SG11202002841PA (en) 2020-04-29
RU2020114960A (ru) 2021-10-28
PH12020550185A1 (en) 2021-03-01

Similar Documents

Publication Publication Date Title
BR112020006246A2 (pt) Método para controle do peso de um sujeito em necessidade
Hildreth et al. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study
JP2020019790A (ja) プラダー・ウィリー症候群を治療する方法
CN116867505A (zh) 替西帕肽治疗方法
Majeed et al. Effects of recombinant irisin on body mass index, serum insulin, luteinizing hormone and testosterone levels in obese female BALB/c mice
BRPI0712051A2 (pt) combinação de análogos de somatostatina com antagonista de receptor do hormÈnio de crescimento ou dopamina
US20240277745A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
BR122025013280A2 (pt) Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2
Snehalatha et al. Metformin in prevention of type 2 diabetes
BR122024015868A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso
BR122024015864A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
CN110636847A (zh) 用于预防及治疗肌肉疾病的组合物
US20250170091A1 (en) Uses of selective androgen receptor modulator (sarm) compounds in chronic weight management
KR102246627B1 (ko) Ｈｍｂａ를 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물
RU2800651C2 (ru) Семаглутид в лекарственной терапии
US20250228804A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
Kenawy et al. Response of Glycated Hemoglobin to Diabetes Remission Outcome Program in Type 2 Diabetes Mellitus
Fife et al. Lymphoedema in bariatric patients
Sanchetee et al. Diabetes and Cancer
Kimonis et al. Glycemic Impact of Long-Term Use of Diazoxide Choline Controlled-Release Tablets in Patients with Prader-Willi syndrome or with Very High Triglycerides
De Ng et al. Pharmacological management update: clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients
Jovanovic et al. Therapy choice-Therapy possibility in PCOS infertility patients

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024015864-7 PROTOCOLO 870240065542 EM 02/08/2024 11:45.O PEDIDO FOI DIVIDIDO NO BR122024015868-0 PROTOCOLO 870240065553 EM 02/08/2024 12:07.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.1 NA RPI NO 2824 DE 18/02/2025 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025013280-2 PROTOCOLO 870250053867 EM 26/06/2025 15:59.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]